CD274 and enterocolitis: Correspondingly, CTLA-4 inhibitors (e.g., ipilimumab and tremelimumab)—alone or in combination—are more frequently associated with GI irAEs, such as enterocolitis or hepatitis, as opposed to PD-1/PD-L1 blockade alone [6,13,14].